CorMedix – Rezafungin Phase 3 (HSCT Prophylaxis)
CorMedix reported positive Phase 3 results from the ReSPECT trial for rezafungin (REZZAYO), demonstrating non-inferiority to standard antimicrobial regimens for prevention of invasive fungal disease (IFD) in allogeneic hematopoietic stem cell transplant (allo-HSCT) patients.
